Agiremid 100 Agimexpharm treats gastric mucosa lesions (10 blisters x 10 tablets)

Dosage form Box of 10 blisters x 10 tablets
Specifications Rebamipide
Ingredient Agimexpharm

Ingredient

Composition information	Content
Rebamipide	100mg

Uses

Indications

Agiremid drug indicated in the following cases:

Stomach ulcer.

Rebamipid prevents the damage of gastric mucosa in different experimental ulcer models in mice, including ulcers created by stress when soaked in water, due to aspirin, indomethacin, histamine, serotonin and pyloric gasters.

In an ulcerative model produced by acetic acid in mice, the drug promotes healing of stomach ulcers and prevents ulcers recurrence after causing ulceration of 120-140 days.

Preventive or healing effect in the gastritis model

Rebamipid prevents the growth of gastritis caused by taurocholic acid (one of the main ingredients of bile acid) and promotes the healing of mucositis in the gastritis model in experimental mice.

The effect of increasing prostaglandin

Rebamipid increases the concentration of prostaglandin E2 (PGE2) in the mucous mucosa of the mouse. The drug also increases the concentration of PGE2, 15-keto-13,14-dihydro-Pge2 (is a metabolic substance of PGE2) and Prostaglandin I2 (PGI2) in gastric juice.

In healthy men, the drug also shows the effect of increasing PGE2 levels in the stomach lining and protecting the stomach lining from damage from high use of ethanol.

Cell protection effect

In the test mouse Rebamipid shows the effect of protecting the stomach cells, preventing the damage to the mucosa caused by ethanol, strong acids or strong base. In in vitro studies, the drug also protects stomach epithelial cells taken from rabbit fetus cultured against aspirin or taurocholic acid (one of the main ingredients of bile acid).

The effect of increasing mucus

Rebamipid promotes the activity of the gastric enzyme to synthesize glycoprotein with high molecular mass, increasing the amount of mucus on the surface and the soluble mucus of the experimental mouse. Prostaglandin (PGS) endogenous has nothing to do in the increased mucus.

The effect of increasing blood flow into the mucosa

Rebamipid increases blood flow to the gastric mucosa and improves hemodynamic impaired after mouse loss.

Activated on the mucosal fence

Rebamipid usually does not affect the difference possible about transmission through the gastric mucosa in the mouse but it prevents the reduction of possible difference due to ethanol.

Activities on the secretion of the stomach in the stomach

Rebamipid promotes alkaline secretion in the stomach.

effects on the number of mucosal cells

Rebamipid activates the proliferation of stomach mucosa and increases the number of stomach epithelial cells in the mouse.

Effects on the restoration of stomach lining

Rebamipid recovers slow healing of artificial wounds caused by bile acid or hydrogen peroxid in the cellular epithelial cells cultured.

works on the secretion of stomach

Rebamipid does not change the basic secretion of gastric fluid or acid secretion stimulated by the secretion.

Effects on reaction molecules containing oxygen

Rebamipid type hydroxyl radicals directly and prevent Superoxid production due to polyclinic white blood cells. The drug prevents the damage to the gastric mucosal cells caused by oxygen -containing reaction molecules, which are released from neutral leukocytes stimulated by Helicobacter pyloriin in in vitro tests. The drug reduces the peroxid content in lipids in the mucous mucosa to drink indomethacin in a state of stress and prevents the damage to the gastric mucosa.

Effects on inflammatory cell infections in the stomach lining

Rebamipid prevents inflammatory cell infections in the gastritis in mice caused by taurocholic acid and gastric mucosa damage caused by nonsteroidal anti -inflammatory drugs (NSAIDs) or lesions of ischemia /

Effects on cytokin release (Interleukin-8) causing inflammation in the gastric mucosa

Rebamipid is taken orally, preventing the increase in production and releasing Interleukin-8 from the gastric mucosa of the person infected with Helicobacter Pylori. The drug also inhibits the activation of the kappa-B (NF-κB) factor of the cause, preventing the expression of Interleukin-8 MRNA and the production of Interleukin-8 in the epithelial cell cultured with Helicobacter Pylori in In vitro test.

pharmacokinetic pharmacokinetics

plasma concentrations

The following figures indicate Rebamipid pharmacokinetics parameters after taking a single dose of Rebamipid 100 mg in 27 healthy male patients.
Rebamipid pharmacokinetics parameters:

m max = 2.4 ± 1.2 (hours) and cmax = 216 ± 79 (mcg/liter)

Average value ± sd, n = 27, t1/2 is calculated up to 12 hours. However, food does not affect the bioavailability of the drug in humans. In a stable state, Rebamipid concentration in mental hemorrhage is observed in patients with renal fertilizer after the dose is repeated very similar to the values when using a single dose. Therefore, the drug is considered not accumulated. Selling time for plasma cancellation is about 1.5 hours. Repeated drug research shows that the drug does not accumulate in humans.

Rebamipid's absorption tends to be slow when taking medicine at a dose of 150 mg after meals on 6 healthy subjects. However, food does not affect the bioavailability of the drug in humans. Pharmacokinetic parameters obtained from patients with renal failure after using the single dose of rebamipid 100 mg show that the plasma concentration is higher and half a lifetime longer than healthy objects. In a stable state, the plasma rebamipid concentration is recorded in patients with the kidneys after the dose is repeated very close to the simulated values from the only dose. Therefore, the drug is considered not accumulated.

transformation

After giving male healthy adults using a single dose of 600 mg, Rebamipid is mainly excreted in urine in the form of constant drugs. A metabolite has a group of hydroxyl in the 8th place that has been found in the urine. However, this metabolic excretion is only 0.03% of the dose used. The enzyme related to this metabolic formation is Cytochrom P450 3A4 (CYP3A4).

Elimination

When healthy male subjects use a single dose of Rebamipid 100 mg, about 10% of the dose has been excreted in the urine.

linked to protein

In Vitro, Rebamipid test at a concentration of 0.05-5 mcg/ml is added to human plasma, and 98.4%-98.6% of the drug is linked to plasma proteins.

Before taking Agiremid 100 Agimexpharm treats gastric mucosa lesions (10 blisters x 10 tablets)

How to use

Tablets for oral tablets.

Dosage

Gastric ulcer: Rebamipid dose is often used for adults is 100 mg (1 Rebamipid 100 mg) x 3 times/day by oral in the morning, evening and before going to bed.

Treatment of gastric mucosal lesions (corrosion, bleeding, redness and edema) in acute gastritis and exacerbations of chronic gastritis: The dose of Rebamipid is often used for adults is 100 mg (1 Rebamipid 100 mg tablet) x 3 times/day by oral.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when using overdose?

What to do when forgetting 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

The unwanted effect of Rebamipid occurs. Side effects are usually light and cannot be overcome by adjusting the dose. Common effects on the digestive system such as constipation, bloating, diarrhea, nausea and vomiting.

Clinical rare side effects:

shock and anaphylactic reaction: shock and anaphylactic reaction may occur. Need to monitor patients closely. If there are abnormal signs, stop taking the drug and take appropriate treatments. Need to monitor patients closely. If there are abnormal signs, stop taking the drug and take appropriate treatments. Need to monitor patients closely. If there are abnormal signs through testing, medication must be stopped and properly treated. System in the body/Frequency

Unknown numb, dizziness and drowsiness digestive

constipation feeling abdominal distention, nausea, vomiting, heartburn, abdominal pain, taste abnormalities, ... Alkaline Chest drums, fever, flushing face, tongue, cough, and respiratory failure

* * If the transaminase level increases significantly or has fever and rash, it is necessary to stop taking the drug and take appropriate treatments.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Agiremid drugs contraindicated in the following cases:

Sensitive to any ingredients of the drug.

Caution when using

used for the elderly: It is necessary to pay special attention to elderly patients to minimize the risk of gastrointestinal disorders, because physiological, elderly patients are often more sensitive to this drug compared to young patients.

Use for children: The safety of drugs for children has not been established (clinical experience in children is incomplete).

Used for pregnant and lactating women

Pregnancy: Rebamipid should only be used for pregnant women or likely to be pregnant if the benefit of the estimated treatment is thought to be higher than any possible risk (unknown level of the safety of this drug in pregnant women).

Breastfeeding period: Women who are breastfeeding must stop breastfeeding before using Rebamipid (mice studies show that rebamipid is excreted in milk).

The effect of driving and operating machinery

There has been no research on the effect of the drug when driving. A number of patients have been recorded dizziness or drowsiness while taking medicine, such patients need to be cautious when driving or operating machinery.

Medicinal interaction

Medicinal interaction may affect the activity of the drug or cause side effects.

Patients should notify the doctor or pharmacist a list of the drugs and functional foods you are using. Do not use or increase or decrease the dose of the drug without the guidance of a doctor.

Storage

Leave a cool place, avoid light, temperature below 30⁰C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.